bioRxivBioengineeringPreprint
De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors
Edin MuratspahićiD, David Feldman, David E. KimiD, Xiangli QuiD, Ana-Maria BratovianuiD, Paula Rivera-SáncheziD, Jan Hendrik Voss, Emil Peter Thrane HertziD, Mads Jeppesen, Federica Dimitri, Kensuke SakamotoiD, Amrita Nallathambi, Pia Peceli, Jianjun Cao, Brian P. CaryiD, Matthew J. BelousoffiD, Peter KeoviD, Phuc N.H. Trinh, Qingchao CheniD, Yue ReniD, Justyn Fine, Sudha MishraiD, Annu Dalal, Shachie Sinha, Ramanuj BanerjeeiD, , David A. BakeriD
Abstract
G protein-coupled receptors (GPCRs) play key roles in physiology and are central targets for drug discovery and development, but the design of protein agonists and antagonists has been challenging as GPCRs are integral membrane proteins and conformationally dynamic. Here we describe computational de novo design methods and a high throughput "receptor diversion" microscopy-based screen for generating GPCR binding miniproteins with high affinity, potency and selectivity, and the use of these methods to generate agonists for MRGPRX1, NK1R and CCR5, as well as antagonists for CXCR4, CCR5, OXTR, GLP1R, GIPR, GCGR, PTH1R and CGRPR.. Cryo-electron microscopy data reveals atomic-level agreement between designed and experimentally determined structures for CGRPR- and CXCR4-bound antagonists and MRGPRX1-bound agonists. Our de novo design and screening approach opens new frontiers in GPCR drug discovery and development.
- assay: protein structure
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- approach: experimental assay
- Citations
- 22
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling test-time compute
Nabla Bio, Surojit Biswas·bioRxiv·May 28, 2025
- A Rapid and Universal Pipeline for High-Resolution GPCR Structure Determination through In Silico Construct Optimization and de novo Protein Design
Asato Kojima, Kouki Kawakami, … Hideaki E. KATO·bioRxiv·Apr 6, 2026
- De novo macrocyclic peptide discovery produces potent class A GPCR ligands with diverse pharmacology
Fernando Salgado-Polo, Marin Matic, … Martin B Gustavsson·bioRxiv·Oct 22, 2026
- Blind De Novo Design of Dual Cyclic Peptide Agonists Targeting GCGR and GLP1R
Qiuzhen Li, Elisée Wiita, … Patrick Bryant·bioRxiv·Jun 6, 2025
- Computational design of allosteric pathways reprograms ligand-selective GPCR signaling
Mahdi Hijazi, Dániel Kéri, … P. Barth·bioRxiv·Aug 13, 2025
- De novo Design of A Fusion Protein Tool for GPCR Research
Kaixuan Gao, Xin Zhang, … Xiangyu Liu·Proceedings of the National Academy of SciencesPeer-reviewed·Jul 14, 2025